Cargando…

Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways

Hepatocellular carcinoma (HCC), with its ineffective therapeutic options and poor prognosis, represents a global threat. In the present study, we show that RAD52 motif 1 (RDM1), a key regulator of DNA double‐strand break repair and recombination, is downregulated in HCC tissues and suppresses tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shi‐Lu, Liu, Li‐Li, Wang, Chun‐Hua, Lu, Shi‐Xun, Yang, Xia, He, Yang‐Fan, Zhang, Chris Zhiyi, Yun, Jing‐Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998392/
https://www.ncbi.nlm.nih.gov/pubmed/31670863
http://dx.doi.org/10.1002/1878-0261.12593
_version_ 1783493842156126208
author Chen, Shi‐Lu
Liu, Li‐Li
Wang, Chun‐Hua
Lu, Shi‐Xun
Yang, Xia
He, Yang‐Fan
Zhang, Chris Zhiyi
Yun, Jing‐Ping
author_facet Chen, Shi‐Lu
Liu, Li‐Li
Wang, Chun‐Hua
Lu, Shi‐Xun
Yang, Xia
He, Yang‐Fan
Zhang, Chris Zhiyi
Yun, Jing‐Ping
author_sort Chen, Shi‐Lu
collection PubMed
description Hepatocellular carcinoma (HCC), with its ineffective therapeutic options and poor prognosis, represents a global threat. In the present study, we show that RAD52 motif 1 (RDM1), a key regulator of DNA double‐strand break repair and recombination, is downregulated in HCC tissues and suppresses tumor growth. In clinical HCC samples, low expression of RDM1 correlates with larger tumor size, poor tumor differentiation, and unfavorable survival. In vitro and in vivo data demonstrate that knockdown of RDM1 increases HCC cell proliferation, colony formation, and cell population at G2/M phase, whereas RDM1 overexpression results in the opposite phenotypes. Mechanistically, RDM1 binds to the tumor suppressor p53 and enhances its protein stability. In the presence of p53, RDM1 suppresses the phosphorylation of Raf and ERK. Overexpression of p53 or treatment with ERK inhibitor significantly abolishes cell proliferation induced by the depletion of RDM1. In addition, overexpression of methyltransferase‐like 3 markedly induces N6‐methyladenosine modification of RDM1 mRNA and represses its expression. Taken together, our study indicates that RDM1 functions as a tumor suppressor and may be a potential prognostic and therapeutic factor for HCC.
format Online
Article
Text
id pubmed-6998392
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-69983922020-02-05 Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways Chen, Shi‐Lu Liu, Li‐Li Wang, Chun‐Hua Lu, Shi‐Xun Yang, Xia He, Yang‐Fan Zhang, Chris Zhiyi Yun, Jing‐Ping Mol Oncol Research Articles Hepatocellular carcinoma (HCC), with its ineffective therapeutic options and poor prognosis, represents a global threat. In the present study, we show that RAD52 motif 1 (RDM1), a key regulator of DNA double‐strand break repair and recombination, is downregulated in HCC tissues and suppresses tumor growth. In clinical HCC samples, low expression of RDM1 correlates with larger tumor size, poor tumor differentiation, and unfavorable survival. In vitro and in vivo data demonstrate that knockdown of RDM1 increases HCC cell proliferation, colony formation, and cell population at G2/M phase, whereas RDM1 overexpression results in the opposite phenotypes. Mechanistically, RDM1 binds to the tumor suppressor p53 and enhances its protein stability. In the presence of p53, RDM1 suppresses the phosphorylation of Raf and ERK. Overexpression of p53 or treatment with ERK inhibitor significantly abolishes cell proliferation induced by the depletion of RDM1. In addition, overexpression of methyltransferase‐like 3 markedly induces N6‐methyladenosine modification of RDM1 mRNA and represses its expression. Taken together, our study indicates that RDM1 functions as a tumor suppressor and may be a potential prognostic and therapeutic factor for HCC. John Wiley and Sons Inc. 2019-12-19 2020-02 /pmc/articles/PMC6998392/ /pubmed/31670863 http://dx.doi.org/10.1002/1878-0261.12593 Text en © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Chen, Shi‐Lu
Liu, Li‐Li
Wang, Chun‐Hua
Lu, Shi‐Xun
Yang, Xia
He, Yang‐Fan
Zhang, Chris Zhiyi
Yun, Jing‐Ping
Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways
title Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways
title_full Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways
title_fullStr Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways
title_full_unstemmed Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways
title_short Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways
title_sort loss of rdm1 enhances hepatocellular carcinoma progression via p53 and ras/raf/erk pathways
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998392/
https://www.ncbi.nlm.nih.gov/pubmed/31670863
http://dx.doi.org/10.1002/1878-0261.12593
work_keys_str_mv AT chenshilu lossofrdm1enhanceshepatocellularcarcinomaprogressionviap53andrasraferkpathways
AT liulili lossofrdm1enhanceshepatocellularcarcinomaprogressionviap53andrasraferkpathways
AT wangchunhua lossofrdm1enhanceshepatocellularcarcinomaprogressionviap53andrasraferkpathways
AT lushixun lossofrdm1enhanceshepatocellularcarcinomaprogressionviap53andrasraferkpathways
AT yangxia lossofrdm1enhanceshepatocellularcarcinomaprogressionviap53andrasraferkpathways
AT heyangfan lossofrdm1enhanceshepatocellularcarcinomaprogressionviap53andrasraferkpathways
AT zhangchriszhiyi lossofrdm1enhanceshepatocellularcarcinomaprogressionviap53andrasraferkpathways
AT yunjingping lossofrdm1enhanceshepatocellularcarcinomaprogressionviap53andrasraferkpathways